Identification and cloning of a novel plasmid-encoded enterotoxin of enteroinvasive Escherichia coli and Shigella strainsJames P. Nataro, J. Glenn Morris, J Seriwatana et al.|Infection and Immunity|1995Cited by 182
Efficacy and safety of suvratoxumab for prevention of Staphylococcus aureus ventilator-associated pneumonia (SAATELLITE): a multicentre, randomised, double-blind, placebo-controlled, parallel-group, phase 2 pilot trialBruno François, Alain Lepape, Miguel Sánchez García et al.|The Lancet Infectious Diseases|2021Cited by 88
635. Efficacy, Pharmacokinetics (PK), and Safety Profile of MEDI3902, an Anti-<i>Pseudomonas aeruginosa</i> Bispecific Human Monoclonal Antibody in Mechanically Ventilated Intensive Care Unit Patients; Results of the Phase 2 EVADE Study Conducted by the Public-Private COMBACTE-MAGNET Consortium in the Innovative Medicines Initiative (IMI) ProgramJean Chastre, Hasan S. Jafri, Bruno François et al.|Open Forum Infectious Diseases|2020Cited by 16
Suvratoxumab Reduces Staphylococcus Aureus Pneumonia in High-Risk ICU Patients: Results of the SAATELLITE StudyBruno François, SAATELLITE Study Group, Miguel Sánchez et al.|Unknown|2019Cited by 6
2839. Efficacy, Pharmacokinetics (PK), and Safety Profile of Suvratoxumab (MEDI4893), a Staphylococcus aureus Alpha Toxin (AT)-Neutralizing Human Monoclonal Antibody in Mechanically Ventilated Patients in Intensive Care Units; Results of the Phase 2 SAATELLITE Study Conducted by the Public-Private COMBACTE ConsortiumBruno François, Hasan S. Jafri, Miguel Sánchez García et al.|Open Forum Infectious Diseases|2019Cited by 5